Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses

Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin‐derived mutant epitopes

(2020) Allan Noé Domínguez‐Romero et al.   IMMUNOLOGY

Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs

(2020) Jesús Zepeda-Cervantes et al.   Frontiers in Immunology

Turning the corner on therapeutic cancer vaccines

(2019) Robert E. Hollingsworth et al.   npj Vaccines

Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer

(2019) Athanasios Mavratzas et al.   Future Oncology

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT

(2018) Elizabeth K. Duperret et al.   MOLECULAR THERAPY

Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy

(2018) Dapeng Zhou et al.   MOLECULES

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

(2018) Julie M. Collins et al.   Expert Review of Vaccines

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma

(2018) Alessandra Lopes et al.   Scientific Reports

Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity

(2017) Katrin Kramer et al.   MOLECULAR THERAPY

Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer

(2017) Braeden Donaldson et al.   Journal for ImmunoTherapy of Cancer

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

(2016) MORENA ANTONILLI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

(2016) Vani Lakshminarayanan et al.   PLoS One

Clinical management of breast cancer heterogeneity

(2015) Dimitrios Zardavas et al.   Nature Reviews Clinical Oncology

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

(2015) O. A. Ali et al.   Cancer Immunology Research

Synthetic Multivalent Glycopeptide-Lipopeptide Antitumor Vaccines: Impact of the Cluster Effect on the Killing of Tumor Cells

(2014) Hui Cai et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist

(2014) Abu-Baker M. Abdel-Aal et al.   CHEMBIOCHEM

Induction of Antitumor Immunity by Dendritic Cells Loaded with Membrane-Translocating Mucin 1 Peptide Antigen

(2014) Saho Kobukai et al.   Translational Oncology

Dendritic-Cell-Based Therapeutic Cancer Vaccines

(2013) Karolina Palucka et al.   IMMUNITY

Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model

(2013) Yu-Qian Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses

(2012) Sara J. McKee et al.   JOURNAL OF CONTROLLED RELEASE

Antigen Incorporated In Virus-like Particles Is Delivered to Specific Dendritic Cell Subsets That Induce An Effective Antitumor Immune Response In Vivo

(2012) Kunyu Li et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Ravi A Madan et al.   LANCET ONCOLOGY

Construction and Characterization of Virus-Like Particles: A Review

(2012) Andris Zeltins   MOLECULAR BIOTECHNOLOGY

Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

(2011) Barbara Romanowski   Human vaccines & immunotherapeutics

Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway

(2011) Stephanie J Win et al.   IMMUNOLOGY AND CELL BIOLOGY

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

(2011) V. Lakshminarayanan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Survivin expression and targeting in breast cancer

(2011) Kumkum Jha et al.   SURGICAL ONCOLOGY-OXFORD

MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells

(2010) E. Lacunza et al.   CANCER GENETICS AND CYTOGENETICS

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes

(2009) Uta B. Hofmann et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response

(2008) Matthew Peacey et al.   VACCINE